AI as the ‘Invisible Analyst’ in Biotech: How Investors Form First Impressions Before They Ever Meet You
By Kaity Kalkbrenner, Head of Growth Strategy, Switzerland
The first interaction an investor has with your company is now invisible. Before they meet your CEO, see your data, or hear your pitch, they interact with something else entirely: an AI generated synthesis.
Across biotech, AI is fast becoming an ‘invisible analyst’, scanning public disclosures, trial readouts, pipelines, leadership signals, sentiment, and competitive positioning in seconds. Long before a management meeting or conference conversation takes place, investors are now forming a preread on companies through AI-mediated insights.
While AI isn’t replacing human judgment (for now…), it’s re-shaping the context in which that judgment is made. And that shift fundamentally changes where differentiation now happens.
The new first meeting happens without you
Investors today use AI to do what once took teams of analysts weeks, sometimes months, to accomplish. AI tools scan and surface patterns across vast volumes of public information, and AI-assisted analyst work is now drawing on significantly broader information sets – around 40% more sources and materially more topics than traditional reports (1).
The result? Perceptions have already been made based on the ability to synthesize massive amounts of data faster than ever before. By the time an investor walks into a meeting, they often arrive with a working narrative already formed. AI is the new baseline and first impression. The question is no longer how to tell your story, but how to elevate what they already know (and, potentially course correct what AI might have misunderstood…)
AI as the invisible analyst: what it sees (and what it misses)
AI is increasingly good at a number of things:
- It excels at pattern recognition across public information
- It benchmarks companies quickly and consistently against peer
- It surfaces inconsistencies or gaps between what companies say and what they do.
In many ways, AI is very good at highlighting where a story doesn’t quite hold together. But breadth doesn’t automatically create clarity. In some AI-assisted analyst environments, research suggests forecast error rates have increased significantly (59%), highlighting a critical limitation: interpretation becomes harder as volume increases. AI can expand the aperture, but it still struggles with meaning, prioritisation, and intent (2).
AI doesn’t truly understand conviction, credibility built over time, and nuances in leadership judgment or culture. The key insight is this: AI doesn’t replace judgment; it shapes it.
When everyone has access to the same “pre-read,” differentiation changes
This shift is happening alongside a broader change in the investment ecosystem itself. AI is no longer just a tool investors use, it’s what they invest in (both with their capital, and with their time). AI-related investments now represent the majority of global venture capital activity (61%), reflecting how central AI has become to the system as a whole. At the same time, the tools investors rely on are spreading rapidly: generative AI adoption among businesses has nearly doubled in a single year (from 33% in 2023 to 65% in 2024), meaning similar analytical capabilities are now available to almost everyone. The result is analytical convergence (3).
How to shift your focus to overcome analytical convergence
When everyone is using comparable tools to generate an initial view, the pre-read starts to look increasingly similar, regardless of who is doing the reading. And when the first read flattens, differentiation has to move elsewhere.
In this environment, decks and data alone no longer differentiate. When working to overcome analytical convergence, decks and data alone no longer differentiate. You need to lean into nuance and context. Give the data meaning, a single-focus, and cultural context. Why does it matter and what story are we telling? This is where the shift begins: away from information, and toward interpretation.
What starts to matter more is relational value:
- Consistency of narrative over time
- Visibility of leadership thinking
- Signals of long-term credibility beyond individual milestones
The move is subtle but significant: from telling your story to earning belief in it.
The human layer investors still look for
AI helps investors move faster through larger opportunity sets and surface signals earlier. But despite that acceleration, final investment decisions still rely on human judgment – on confidence in leadership, clarity of strategy, and belief in a team’s ability to navigate uncertainty over time.
Investors still look for leadership signals that help them answer one fundamental question: can I trust this team to deliver, adapt, and make good decisions when the data isn’t clear?
They look for leadership presence that:
- Shows clarity on strategy, not just progress
- Explains decisions, not simply results
- Articulates trade‑offs, not just outcomes
They also pay close attention to thought leadership, not as marketing, but as evidence of how leaders think. Strong thought leadership:
- Adds interpretation rather than repeating data
- Explains why choices were made, not just what happened
- Makes uncertainty legible without undermining confidence
And importantly, moments like industry conferences are no longer about introducing something entirely new. They are opportunities to validate what AI has already surfaced, and either reinforce or correct the emerging narrative.
What this means for biotech leaders in 2026 and beyond
A few implications are becoming clear.
First, visibility is now cumulative, not episodic. Silence between milestones doesn’t create neutrality, it creates space for AI to fill in the gaps. The companies who shape their narrative in those silent moments will have an advantage.
Second, narrative coherence matters as much as novelty. Disjointed signals across time, channels, or leaders are amplified, not softened, by AI. Align early and AI will tell a more cohesive story from the start.
Third, thought leadership needs to be reframed. Not as promotion, but as context setting for how your company is interpreted when you’re not in the room. Context, not content, is now critical to differentiate.
In an AI-mediated world, leadership visibility isn’t optional. It’s part of how credibility is built, tested, and sustained.
Relationships still matter, they just start earlier
AI will increasingly mediate first impressions in biotech investing. That’s now a reality.
But belief, trust, and conviction remain fundamentally human. They are built through clarity, consistency, and leadership judgment that is shown over time, in public, and under scrutiny.
The real question is no longer whether AI is part of the investor journey, it’s whether companies are actively shaping the story AI tells on their behalf.
How are you thinking about AI’s role in shaping investor perception today?
Get in touch with us
If you’re ready to transform healthcare into what it should be, we’d love to connect.
This article was originally published on LinkedIn. You can view the original post here and learn more about the author on LinkedIn here.
Sources
(1) arXiv:2512.19705 [q-fin.ST]
(2) Hellmann, Thomas, and others, ‘The Impact of AI on Venture Capital: A Critical Outlook’ (6 Mar. 2026), in Florian Möslein, and Mari Sako (eds), Business, Industry, and Finance, in Philipp Hacker (ed.), Oxford Intersections: AI in Society (Oxford, online edn, Oxford Academic, 20 Mar. 2025 – ), https://doi.org/10.1093/9780198945215.003.0146
